Andrew Silagy

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4784889/publications.pdf

Version: 2024-02-01

1040056 1058476 23 235 9 14 citations h-index g-index papers 23 23 23 394 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	The association between modifiable perioperative parameters and renal function after nephrectomy. BJU International, 2022, 129, 380-386.	2.5	2
2	Systemic immunological determinants of oncological outcomes after surgery for localized renal cell carcinoma. Clinical Genitourinary Cancer, 2022, , .	1.9	0
3	A Targetable Myeloid Inflammatory State Governs Disease Recurrence in Clear-Cell Renal Cell Carcinoma. Cancer Discovery, 2022, 12, 2308-2329.	9.4	7
4	The Clinicopathologic and Molecular Landscape of Clear Cell Papillary Renal Cell Carcinoma: Implications in Diagnosis and Management. European Urology, 2021, 79, 468-477.	1.9	35
5	Identifying Clear Cell Renal Cell Carcinoma Coexpression Networks Associated with Opioid Signaling and Survival. Cancer Research, 2021, 81, 1101-1110.	0.9	10
6	Putative Drivers of Aggressiveness in TCEB1-mutant Renal Cell Carcinoma: An Emerging Entity with Variable Clinical Course. European Urology Focus, 2021, 7, 381-389.	3.1	28
7	Therapy-relevant gene signatures in the high risk localized renal cell carcinoma setting: Transcriptomic data from patients receiving placebo on a randomized phase III trial (PROTECT) Journal of Clinical Oncology, 2021, 39, 353-353.	1.6	O
8	Immune checkpoint blockade in renal cell carcinoma. Journal of Surgical Oncology, 2021, 123, 739-750.	1.7	13
9	Surgical innovation revisited: A historical narrative of the minimally invasive "Agarwal sliding lip renorrhaphy―technique for partial nephrectomy and its application to an Australian cohort. BJUI Compass, 2021, 2, 211-218.	1.3	6
10	A qualitative framework of non-selection factors for cytoreductive nephrectomy. World Journal of Urology, 2021, 39, 3359-3365.	2.2	3
11	Prevalence and Landscape of Actionable Genomic Alterations in Renal Cell Carcinoma. Clinical Cancer Research, 2021, 27, 5595-5606.	7.0	12
12	Evolving biological associations of upfront cytoreductive nephrectomy in metastatic renal cell carcinoma. Cancer, 2021, 127, 3946-3956.	4.1	12
13	Somatic mutations as preoperative predictors of metastases in patients with localized clear cell renal cell carcinoma $\hat{a} \in \text{Month}(G)$ analysis. Urologic Oncology: Seminars and Original Investigations, 2021, 39, 791.e17-791.e24.	1.6	3
14	The Role of Cytoreductive Nephrectomy for Sarcomatoid Renal Cell Carcinoma: A 29-Year Institutional Experience. Urology, 2020, 136, 169-175.	1.0	9
15	The Association Between Small Primary Tumor Size and Prognosis in Metastatic Renal Cell Carcinoma: Insights from Two Independent Cohorts of Patients Who Underwent Cytoreductive Nephrectomy. European Urology Oncology, 2020, 3, 47-56.	5.4	20
16	Preoperative nomogram predicting 12-year probability of metastatic renal cancer – evaluation in a contemporary cohort. Urologic Oncology: Seminars and Original Investigations, 2020, 38, 853.e1-853.e7.	1.6	6
17	Impact of intraoperative opioid and adjunct analgesic use on renal cell carcinoma recurrence: role for onco-anaesthesia. British Journal of Anaesthesia, 2020, 125, e402-e404.	3.4	15
18	Predictors of long-term renal function after kidney surgery for patients with preoperative chronic kidney disease. Canadian Urological Association Journal, 2020, 15, E103-E109.	0.6	0

ANDREW SILAGY

#	Article	lF	CITATIONS
19	An evaluation of the role of tumor load in cytoreductive nephrectomy. Canadian Urological Association Journal, 2020, 14, E625-E630.	0.6	1
20	Comprehensive Genomic Analysis of Translocation Renal Cell Carcinoma Reveals Copy-Number Variations as Drivers of Disease Progression. Clinical Cancer Research, 2020, 26, 3629-3640.	7.0	30
21	The predictive role of preoperative and postoperative neutrophil-lymphocyte ratio in sarcomatoid renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 916-923.	1.6	8
22	Harnessing the Genomic Landscape of the Small Renal Mass to Guide Clinical Management. European Urology Focus, 2019, 5, 949-957.	3.1	9
23	Clinicopathologic features associated with survival after cytoreductive nephrectomy for nonclear cell renal cell carcinoma. Urologic Oncology: Seminars and Original Investigations, 2019, 37, 811.e9-811.e16.	1.6	6